Ask AI
ProCE Banner Activity

Individualizing Myelofibrosis Treatment in the Era of Multiple JAK Inhibitors

Clinical Thought

In this commentary, an expert discusses individualized treatment selection and sequencing in myelofibrosis, emphasizing the integration of prognostic risk, clinical phenotype, and patient-specific factors. The commentary examines the role of anemia, thrombocytopenia, splenomegaly, and symptom burden in guiding JAK inhibitor selection, including considerations for ruxolitinib, fedratinib, pacritinib, and momelotinib. Drawing on clinical trial evidence, prescribing information, and expert experience, the discussion addresses assessment of treatment response, recognition of JAK inhibitor resistance or intolerance, and strategies for managing evolving clinical needs. The expert also highlights the importance of early transplant evaluation, clinical trial participation, and patient-centered decision-making to inform treatment sequencing and optimize care throughout the disease course.

Released: November 09, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education In partnership with Smart Patients, Inc.

ProCE Banner

Supporters

This educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Sobi.

GSK

Incyte Corporation

Sobi

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is intended for oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who care for patients with myelofibrosis. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop evidence-based supportive care strategies to manage treatment-related adverse AEs in patients with MF

  • Integrate strategies for coordinated multidisciplinary care team and shared decision-making strategies to optimize patient-centered management of myelofibrosis, including symptom control and quality-of-life considerations

Financial Disclosures

Primary Author

Abdulraheem Yacoub, MD, has no relevant relationships to disclose.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.